Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Holdings Raised by BBR Partners LLC

BBR Partners LLC grew its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 800.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 270,000 shares of the biopharmaceutical company’s stock after acquiring an additional 240,000 shares during the period. BBR Partners LLC owned 0.11% of Lexicon Pharmaceuticals worth $454,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Rhumbline Advisers grew its stake in Lexicon Pharmaceuticals by 13.3% in the second quarter. Rhumbline Advisers now owns 152,785 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 17,940 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Lexicon Pharmaceuticals by 116.1% in the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares during the last quarter. Bank of New York Mellon Corp raised its position in Lexicon Pharmaceuticals by 37.6% during the second quarter. Bank of New York Mellon Corp now owns 401,908 shares of the biopharmaceutical company’s stock valued at $675,000 after acquiring an additional 109,902 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $912,000. Finally, Virtu Financial LLC bought a new stake in Lexicon Pharmaceuticals in the first quarter worth approximately $105,000. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Stock Performance

NASDAQ:LXRX opened at $1.62 on Friday. The firm has a market capitalization of $398.90 million, a PE ratio of -1.95 and a beta of 1.35. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.92 and a 1 year high of $3.73. The firm’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.94.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. The business had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $2.74 million. Lexicon Pharmaceuticals had a negative return on equity of 105.38% and a negative net margin of 5,509.34%. During the same quarter in the previous year, the firm earned ($0.22) EPS. On average, sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.69 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on LXRX shares. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday. StockNews.com raised Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.50.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.